For HER2-enriched subtype stage IV breast cancer patients, we also observed that younger patients had a better prognosis than patients aged 51 to 60 years (HR, 0.70; 95% CI, 0.52-0.94) after controlling sociodemographic factors and clinical-pathological characteristics. The gene discussed is ERBB2; the disease is breast carcinoma.